An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer

Abstract The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody‐CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2‐positive cancer is introd...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Seungju Yang, San Hae Im, Ju Yeon Chung, Juhee Lee, Kyung‐Hun Lee, Yoo Kyung Kang, Hyun Jung Chung
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-06-01
coleção:	Advanced Science
Assuntos:	antibody conjugation cancer therapy CRISPR/Cas in vivo gene editing specific delivery
Acesso em linha:	https://doi.org/10.1002/advs.202308763
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!